Therapeutic Efficacy of Bevacizumab for Age-Related Macular Degeneration: What are the Implications of CATT for Routine Management?

Author： Ziemssen Focke   Sobolewska Bianka  

Publisher： Adis International

ISSN： 1170-229X

Source： Drugs & Aging, Vol.28, Iss.11, 2011-11, pp. : 853-865

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration: What is the Evidence?

By Ziemssen Focke  

Drugs & Aging, Vol. 26, Iss. 4, 2009-05 ,pp. : 295-320

Adis International

Access to resources Recommend Favorite

Verteporfin worth it for age-related macular degeneration in the UK?

By  

Inpharma, Vol. 1, Iss. 1345, 2002-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

What's new in disease management?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 252, 2000-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches

By  

Current Molecular Pharmacology, Vol. 4, Iss. 3, 2011-11 ,pp. : 196-232

Bentham Science Publishers

Access to resources Recommend Favorite

The Burden of Age-Related Macular Degeneration

By Schmier Jordana K.   Jones Mechelle L.   Halpern Michael T.  

PharmacoEconomics, Vol. 24, Iss. 4, 2006-01 ,pp. : 319-334

Adis International

Access to resources Recommend Favorite